Finance

Lists
Outlook: 30.8% bullish·23.1% bearish
Go to analysis
CTNM:NASDAQ
Contineum Therapeutics Inc
$13.60
+2.99%
(+0.39) 1D
Sep 18, 10:25:50 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTNM...
Open
$13.23
High
$13.70
Low
$13.14
Mkt. cap
511.84M
Avg. vol.
524.57K
Volume
45.51K
52-wk high
$17.78
52-wk low
$8.60
EPS
-$1.74
Shares outstanding
32.96M
No. of employees
51
Open
$13.23
High
$13.70
Low
$13.14
Mkt. cap
511.84M
Avg. vol.
524.57K
Volume
45.51K
52-wk high
$17.78
52-wk low
$8.60
EPS
-$1.74
Shares outstanding
32.96M
No. of employees
51
News stories
From web sources and news partners
About Contineum Therapeutics Inc
CEO-
Employees51
Founded2009
Headquarters-
SectorPharmaceutical industry
Websitecontineum-tx.com
Analyst ratings
Based on 8 analysts giving stock ratings to CTNM in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CTNM in the last 3 months.
Highest
Current $13.60
$28.00 (+105.81%)
Average
$22.43 (+64.87%)
Lowest
$18.00 (+32.30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Leerink Partners
Buy
Maintained
$22.00
+61.7%
09/16/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$24.00
+76.4%
09/15/2026
Charles Moore
Robert W. Baird
Buy
Maintained
$19.00
+39.7%
09/15/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$28.00
+105.8%
09/15/2026
Gaurav Maini
LifeSci Capital
Buy
Reiterated
$23.00
+69.1%
09/14/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
09/14/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$23.00
+69.1%
09/03/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
$18.00
+32.3%
08/17/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.40 / -$0.45
+10.83%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.50M
12.00M
11.14M
11.97M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.43M
5.12M
5.76M
5.45M
Operating expense
14.93M
17.12M
16.90M
17.43M
Total operating expenses
14.93M
17.12M
16.90M
17.43M
Operating income
-14.93M
-17.12M
-16.90M
-17.43M
Other non operating income
183.00K
-51.00K
-57.00K
-68.00K
EBT including unusual items
-12.79M
-15.16M
-14.46M
-15.15M
EBT excluding unusual items
-12.79M
-15.16M
-14.46M
-15.15M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.79M
-15.16M
-14.46M
-15.15M
Net profit margin
-
-
-
-
Earnings per share
-0.45
-0.49
-0.39
-0.40
Interest and investment income
1.96M
2.01M
2.50M
2.34M
Interest expense
-
-
-
-
Net interest expenses
1.96M
2.01M
2.50M
2.34M
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.85M
-17.03M
-16.82M
-17.29M
Gain or loss from assets sale
-
-
2.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps